Tissue-agnostic cancer drug

Tissue-agnostic cancer drugs are antineoplastic drugs that treat cancers based on the mutations that they display, instead of the tissue type in which they appear. Tissue-agnostic drugs include Pembrolizumab (Keytruda) and Larotrectinib (Vitrakvi). 
History.
Petrolizumab was approved by the US Food and Drug Administration In May 2017.
Larotrectinib was approved by the FDA in November, 2018.
Loxo-292 received priority review in September 2018.
Other drugs under development include Entrectinib, BLU-667, Loxo-195 and Anti-ERBB3 antibody.